Wall Street brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will announce earnings per share (EPS) of ($0.24) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for BioDelivery Sciences International’s earnings, with estimates ranging from ($0.31) to ($0.20). BioDelivery Sciences International reported earnings per share of ($0.31) during the same quarter last year, which would suggest a positive year over year growth rate of 22.6%. The firm is scheduled to report its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full year earnings of $0.18 per share for the current financial year, with EPS estimates ranging from ($0.03) to $0.28. For the next financial year, analysts forecast that the business will report earnings of ($0.66) per share, with EPS estimates ranging from ($0.82) to ($0.50). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Monday, May 15th. The specialty pharmaceutical company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.09 by $0.49. The company had revenue of $29.48 million during the quarter, compared to analysts’ expectations of $27.07 million. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%.

A number of equities research analysts have commented on BDSI shares. HC Wainwright set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Saturday, June 10th. ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Saturday, April 8th. Finally, Janney Montgomery Scott lifted their price objective on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a “fair value” rating in a research note on Monday. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $4.00.

Shares of BioDelivery Sciences International (NASDAQ BDSI) traded down 4.29% during trading on Tuesday, reaching $3.35. 1,003,648 shares of the company traded hands. The company’s market capitalization is $185.34 million. BioDelivery Sciences International has a 52 week low of $1.50 and a 52 week high of $3.60. The company’s 50-day moving average price is $2.71 and its 200-day moving average price is $2.13.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/25/brokerages-anticipate-biodelivery-sciences-international-inc-bdsi-will-post-earnings-of-0-24-per-share.html.

Several large investors have recently modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in shares of BioDelivery Sciences International during the fourth quarter worth $142,000. Searle & CO. raised its stake in shares of BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock worth $410,000 after buying an additional 49,850 shares during the last quarter. Grandeur Peak Global Advisors LLC raised its stake in shares of BioDelivery Sciences International by 5.9% in the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after buying an additional 56,550 shares during the last quarter. Blair William & Co. IL raised its stake in shares of BioDelivery Sciences International by 37.6% in the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock worth $1,386,000 after buying an additional 189,484 shares during the last quarter. Finally, NEXT Financial Group Inc raised its stake in shares of BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 4,000 shares during the last quarter. Institutional investors and hedge funds own 40.33% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.